Beigene Stock Working Capital
| 688235 Stock | 176.00 0.32 0.18% |
BeiGene fundamentals help investors to digest information that contributes to BeiGene's financial success or failures. It also enables traders to predict the movement of BeiGene Stock. The fundamental analysis module provides a way to measure BeiGene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BeiGene stock.
The current year's Net Working Capital is expected to grow to about 3.7 B, whereas Change In Working Capital is projected to grow to (352 M). BeiGene | Working Capital |
BeiGene Company Working Capital Analysis
BeiGene's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current BeiGene Working Capital | 2.39 B |
Most of BeiGene's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BeiGene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
BeiGene Capital Lease Obligations
Capital Lease Obligations |
|
In accordance with the company's disclosures, BeiGene has a Working Capital of 2.39 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all China stocks is notably lower than that of the firm.
BeiGene Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BeiGene's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics of similar companies.BeiGene is currently under evaluation in working capital category among its peers.
BeiGene Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0958 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 152.56 B | ||||
| Shares Outstanding | 115.06 M | ||||
| Shares Owned By Insiders | 4.16 % | ||||
| Shares Owned By Institutions | 32.72 % | ||||
| Price To Book | 9.79 X | ||||
| Price To Sales | 6.99 X | ||||
| Revenue | 2.46 B | ||||
| Gross Profit | (511.06 M) | ||||
| EBITDA | (5.58 B) | ||||
| Net Income | (881.71 M) | ||||
| Total Debt | 688.37 M | ||||
| Book Value Per Share | 226.72 X | ||||
| Cash Flow From Operations | (1.16 B) | ||||
| Earnings Per Share | (4.57) X | ||||
| Target Price | 196.06 | ||||
| Number Of Employees | 10.6 K | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 164.41 B | ||||
| Total Asset | 5.81 B | ||||
| Retained Earnings | (7.96 B) | ||||
| Working Capital | 2.39 B | ||||
| Net Asset | 5.81 B |
About BeiGene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.